glp-1 drugs pharmaceutical companies partnerships 2025 Antagonists Increase Plan Drug Spend - What's Next 2025 Pharmacy in Focus Report:
Description
The GLP-1 receptor agonist dose should be lowered and patients should be encouraged to increase meal size and frequency
The most common ones are: Nausea Vomiting Diarrhea or constipation Mild fatigue Rarely, pancreatitis or gallbladder issues Most of these symptoms are manageable and tend to improve as your body adjusts
Ayala, J
Saxenda (liraglutide): Manufactured by Novo Nordisk and FDA-approved for chronic weight management, Saxenda has been named in MDL 3163
